Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Nephrology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Nephrology Other
    Rituximab Significantly Reduces Renal Injury in Membranous Nephropathy - (DGNews)
    Rituximab and intravenous immune globulin for desensitization during renal transplantation - (N Engl J Med)
    Intranasal Desmopressin Loses Indication for Primary Nocturnal Enuresis in Canada - (DGNews)
    Cinacalcet Balances Calcium, Parathyroid Hormone Levels in Dialysis Patients With ESRD - (DGNews)
    Kidney Disease Linked to Lower Medication Use After Heart Attack - (DGNews)

    News archive

     Recent webcasts/CME - Nephrology Other
    • Treating Anemia in Chronic Kidney Disease: Can We Do Better?
    • What Can We Do When Patients Don't Respond to Treatment of Anemia in Chronic Kidney Disease?
    • Bridging Interdisciplinary and Resource Gaps in CKD-Anemia Management
      The Cardio-Renal Link: Preventing Cardiovascular Disease and Diabetes in Renal Transplant Recipients
      Use of Direct Thrombin Inhibitors for Treating Non-St-Segment Elevation Acute Coronary Syndromes in Special Patient Groups: Women, Diabetics, the Elderly, and Chronic Renal Insufficiency

      Webcasts/CME archive

       Recent cases - Nephrology Other
        Successful Transureteropyelostomy after Heminephrectomy of a Bilateral Hydronephrotic Horseshoe Kidney: A Case Report
        Acute Renal Infarction Due to Renal Fibromuscular Dyplasia: A Case of Mistaken Identity
        Goodpasture's Syndrome with Positive C-ANCA and Normal Renal Function: A Case Report
        A Clay-Shoveler's Fracture with Renal Transplantation and Osteoporosis: A Case Report
        Spontaneous Rupture of an Infected Renal Cyst and External Drainage Through a Lumbar Surgical Scar in a Male Patient with Cervical Spinal Cord Injury: A Case Report

        Cases archive
          




        my personal edition > nephrology other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        No Difference between N-Acetylcysteine and Fenoldopam for Thwarting Contrast-Induced Nephropathy: Presented at AHA

        By Jill Stein

        NEW ORLEANS, LA -- November 8, 2004 -- A randomized study failed to show a significant difference in the ability of oral N-acetylcysteine (NAC) and intravenous fenoldopam (FEN) to prevent the deterioration in renal function or the rate of contrast-induced nephropathy after contrast dye administration during cardiac catheterization.

        The data were reported here on November 6th at the American Heart Association Scientific Sessions 2004 by Tien M.H. Ng, PharmD, and a group with the University of Nebraska in Omaha. Dr. Ng is currently assistant clinical professor of medicine, University of Southern California, Los Angeles, California.

        In the study, cardiac catheterization patients with preexisting stable renal insufficiency were randomized to receive NAC 600 mg orally twice daily for 4 doses or FEN 0.1 mcg/kg/min intravenously for a minimum of 8 hours.

        Randomization included stratification for diabetes. Non-insulin-dependent subjects received concomitant intravenous hydration with 0.9% sodium chloride at a rate of 1 mL/kg/hr; insulin-dependent patients were given 5% dextrose in normal saline.

        The study was stopped after 95 patients (mean age 68 years, 25% female, 42% diabetic, mean baseline serum creatinine 1.5 ±0.4 mg/L) were randomized; 84 patients completed follow-up.

        Overall, there were no differences between NAC and FEN in the mean change in serum creatinine at 72 hours (0.20 ±0.72 vs 0.08 ±0.48 mg/L, respectively, P = 0.4) or the incidence of contrast-induced nephropathy (5 vs 8, P = 0.4) between the 2 therapies.

        The similarity in efficacy was consistent regardless of diabetic status, gender, baseline renal function, age, or contrast volume.

        Dr. Ng cautioned that the study was limited by its early termination, the level of baseline renal insufficiency, the absence of a placebo or combination comparison, and the fact that it was insufficiently powered to determine the optimal FEN dose.

        Contrast-induced nephropathy refers to an acute impairment of renal function occurring 24 to 48 hours and up to 5 days after the administration of radiographic contrast dye. The reported incidence of this complication varies between 4% and 70%, and its development has been linked to significant morbidity and mortality. Contrast material exerts multiple effects on renal physiology that can contribute to impaired renal function, including vasoconstrictive decreases in renal perfusion and oxidative renal damage.


        [Presentation title: Randomized Comparison of Oral N-Acetylcysteine to Intravenous Fenoldopam for the Prevention of Contrast-Induced Nephropathy (CAFCIN Study). Abstract 1796]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send